Cinven Reportedly Grabs Theramex for €2.6B as Carlyle and PAI Cash Out

Cinven is snapping up women's healthcare group Theramex for roughly €2.6 billion, according to the Financial Times, a deal that hands Carlyle and PAI Partners a payout worth more than twice what they paid. The private equity pair picked up the London-based company for about €1.2 billion back in 2022.

Theramex isn't a niche player. It makes treatments for menopause, fertility, osteoporosis, contraception and uterine health, and it sells across more than 80 countries spanning Europe, Asia, Africa and Latin America. That global footprint is exactly the kind of thing buyout firms chase when they want scale in a defensive sector.

For Carlyle and PAI, the exit is a tidy one. Doubling a business in four years is a strong result in any market, and it lands as private equity firms are finding it harder to hand money back to investors through sales. The FT framed the sale as a notable return amid that tough exit climate.

The move also slots into a busy stretch for European healthcare dealmaking. CapVest went big with a €10 billion acquisition of Stada, and GTCR agreed to take over Zentiva for €4.1 billion. Cinven's play for Theramex adds another multi-billion euro name to that list.

Neither side has confirmed the price publicly, and the figure comes via the FT's reporting. What happens next depends on the usual closing steps — but the headline number already makes this one of the sharper healthcare flips of the year.